Grupo Chileno de Estudio de Linfoma

Epcoritamab + GemOx shows impressive efficacy in transplant-ineligible R/R DLBCL patients per EPCORE NHL-2 Arm 5 trial 🧬💉🩸 •ORR: 85% (CR: 61%) •1 prior line: ORR 90%, CR 74% •≥2 lines: ORR 83%, CR 53% •Median DOCR: 23.6 months •12-month OS with 1 prior line: 69% 📈⏳🧪 Safety •Common AEs: cytopenias & CRS •CRS mostly low-grade, all resolved ⚠️🧠✅ Conclusion: Deep, durable responses support epcoritamab + GemOx as a promising option in R/R DLBCL ineligible for ASCT 📌🔬🛡️ 🔗 Brody et al. Blood 2024; DOI: 10.1182/blood.20240206830 #HemeTwitter #DLBCL #Epcoritamab #CARBTherapy #Lymphoma #BloodCancer #ASCT #Immunotherapy #EPCORE #Hematology #PharmTwitter #OncoTwitter

Congreso de hematopatologia !!!!!

CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients. Ongoin @SWOG S1925 trial evaluates early venetoclax-based treatment for high risk patients. @JCO_ASCO @DebbieMStephens ascopubs.org/doi/full/10.12…

A bright spot 🎇in a meeting full of light was seeing all the connections made at #ASH24. Who did you meet at the meeting? Tag them below!

Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs - British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs) ow.ly/GauQ50TY4CW #lymphoidneoplasia

CONGRESS | #SOHO2024 Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL. Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose modifications and were consistent with individual known safety profiles. #lymsm

Results of the phase III SYMPATICO trial presented at #ASCO24 show that ibrutinib + venetoclax is effective for the treatment of pts with MCL & TP35 mutations, with high CR rates & durable remissions 📝 More news: LymphomaHub.com #lymphoma #MedNews #MedEd @michaelwangmd

A medir y suplementar!! Especialmente acá en Chile , donde el déficit de vitamina d es endémico.

Lymphoma Classifications, How to Develop a Future Unified Taxonomy | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of IV HD-methotrexate CNS prophylaxis & the importance of baseline cerebrospinal fluid analysis [May 10, 2023] Bennett et al. @AjHematology onlinelibrary.wiley.com/doi/abs/10.100… #lymsm #btsm #CNSprophylaxis

🔴Atrial Fibrillation and Cirrhosis: Which Anticoagulant? 🔹Apixaban might present less bleeding risk than rivaroxaban or warfarin. 🔹Apixaban is associated with a roughly 3-percentage-point lower incidence of bleeding events annually ✔️acpjournals.org/doi/10.7326/M2…

🖍️Infografías sobre monitorización y ajuste posológico en antifúngicos: 👉Rol de la monitorización en triazólicos 👉Recomendaciones para cada formulación 👉T de muestreo 👉Nivls valle recomendados 👉Ajustes de D en itra, posa, vori e isavuconazol From: funguseducationhub.org/fungal-tdm/

Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival ashpublications.org/blood/article-…

🚨"Risk of infections with bispecific antibodies in B-cell non-Hodgkin lymphomas and multiple myeloma—The current state.” The review summarizes @US_FDA Approved BsAb. Work led by PGY1 IM, @AmritGonugunta @BrJHaem @MDAndersonNews #BiTE #CART #infections onlinelibrary.wiley.com/doi/pdf/10.111…

Good news for follicular lymphoma patients: #epcoritamab receives positive conditional marketing approval from CHMP/EMA based on phase II NHL-1 study results. Another CD20 x CD3 bispecific antibody available ir.genmab.com/news-releases/… #lymSM

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma astctjournal.org/article/S2666-…

Prepárate para una experiencia de aprendizaje, networking y buena onda en la 2da jornada del GCEL! 26 y 27 de Julio 2024 Double tree by Hilton , av. Kennedy 4422, Vitacura Únete a nosotros y forma parte del cambio en el tratamiento de los linfomas. ¡No faltes!

Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10 - The Lancet Haematology thelancet.com/journals/lanha…

Fecha: [26 y 27 de Julio] Horario: [8:30 am ] Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura] ¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL #Linfoma #Networking #Hematología

¡No te pierdas la segunda jornada del Grupo Chileno de Estudio del Linfoma (GCEL)! Te invitamos a participar de esta imperdible cita que reunirá a algunos de los profesionales más destacados en el estudio y tratamiento del linfoma en Chile y en Latinoamérica.